Deutsche Bank AG Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Deutsche Bank AG lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,630,160 shares of the medical equipment provider's stock after purchasing an additional 196,240 shares during the quarter. Deutsche Bank AG owned about 0.73% of Hologic worth $100,695,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Hologic during the 1st quarter worth $42,000. Raiffeisen Bank International AG acquired a new position in Hologic during the 4th quarter worth about $49,000. Allworth Financial LP lifted its stake in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 216 shares in the last quarter. Larson Financial Group LLC lifted its stake in Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 722 shares in the last quarter. Finally, West Financial Advisors LLC acquired a new position in Hologic during the 1st quarter worth about $50,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. UBS Group increased their target price on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and increased their target price for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Morgan Stanley increased their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Finally, Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $77.83.

Hologic Stock Down 1.3%

Shares of HOLX traded down $0.90 during mid-day trading on Thursday, reaching $68.08. The company's stock had a trading volume of 1,475,282 shares, compared to its average volume of 2,797,811. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The stock has a market cap of $15.14 billion, a PE ratio of 28.25, a price-to-earnings-growth ratio of 2.47 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company's 50 day moving average is $65.43 and its 200 day moving average is $62.69.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business posted $1.06 EPS. The business's revenue for the quarter was up 1.2% on a year-over-year basis. Equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.